NCT03604198 2026-04-21Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeCorcept TherapeuticsPhase 2 Active not recruiting125 enrolled
NCT05257408 2025-04-16Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerCorcept TherapeuticsPhase 3 Active not recruiting381 enrolled 3 FDA